Catabasis Pharmaceuticals, Inc. (CATB:NASDAQ) Investor Relations Material

Overview

Catabasis Pharmaceuticals is a company committed to finding innovative therapies to improve the lives of patients suffering from Duchenne muscular dystrophy. The company's lead program, edasalonexent, is currently in Phase 3 development and works by inhibiting the NF-kB protein. Catabasis's mission is to bring hope and transformative treatments to patients and their families.

Annual Reports

Frequently Asked Questions

What is Catabasis Pharmaceuticals, Inc.'s ticker?

Catabasis Pharmaceuticals, Inc.'s ticker is CATB

What exchange is Catabasis Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Catabasis Pharmaceuticals, Inc.'s headquarters?

They are based in Boston, Massachusetts

How many employees does Catabasis Pharmaceuticals, Inc. have?

There are 11-50 employees working at Catabasis Pharmaceuticals, Inc.

What is Catabasis Pharmaceuticals, Inc.'s website?

It is https://www.catabasis.com/index.php

What type of sector is Catabasis Pharmaceuticals, Inc.?

Catabasis Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is Catabasis Pharmaceuticals, Inc.?

Catabasis Pharmaceuticals, Inc. is in the Biotechnology industry

Who are Catabasis Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are Catabasis Pharmaceuticals, Inc.'s industry peers:

- AorTech International plc

- PDS Biotechnology

- Neurocrine Biosciences

- Veru

- Auris Medical Holding Ltd.